Advertisement

Combined epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A and the histone deacetylase inhibitor panobinostat against human AML cells

Warren Fiskus, Yongchao Wang, Arun Sreekumar, Kathleen M. Buckley, Huidong Shi, Anand Jillella, Celalettin Ustun, Rekha Rao, Pravina Fernandez, Jianguang Chen, Ramesh Balusu, Sanjay Koul, Peter Atadja, Victor E. Marquez and Kapil N. Bhalla

Article Information

Citation 
vol. 114 no. 13 2733-2743
PubMed 

Print ISSN 
Online ISSN 
History 
  • Submitted March 27, 2009
  • Accepted July 6, 2009
  • Published online September 24, 2009.

Article Versions


Contributors 
  • Warren Fiskus, 1Medical College of Georgia Cancer Center, Augusta;
  • Yongchao Wang, 1Medical College of Georgia Cancer Center, Augusta;
  • Arun Sreekumar, 1Medical College of Georgia Cancer Center, Augusta;
  • Kathleen M. Buckley, 1Medical College of Georgia Cancer Center, Augusta;
  • Huidong Shi, 1Medical College of Georgia Cancer Center, Augusta;
  • Anand Jillella, 1Medical College of Georgia Cancer Center, Augusta;
  • Celalettin Ustun, 1Medical College of Georgia Cancer Center, Augusta;
  • Rekha Rao, 1Medical College of Georgia Cancer Center, Augusta;
  • Pravina Fernandez, 1Medical College of Georgia Cancer Center, Augusta;
  • Jianguang Chen, 1Medical College of Georgia Cancer Center, Augusta;
  • Ramesh Balusu, 1Medical College of Georgia Cancer Center, Augusta;
  • Sanjay Koul, 1Medical College of Georgia Cancer Center, Augusta;
  • Peter Atadja, 2Novartis Institute for Biomedical Research, Cambridge, MA; and
  • Victor E. Marquez, 3National Institutes of Health, Bethesda, MD
  • Kapil N. Bhalla, 1Medical College of Georgia Cancer Center, Augusta;

Altmetric.com Statistics

The Altmetric score is a weighted count of online attention designed to reflect the volume and reach of online engagement surrounding an individual research output